{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T20:01:34Z","timestamp":1779998494642,"version":"3.53.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Guidelines recommend fluoroquinolones or cotrimoxazole for urinary tract infections in men (UTIm), but safety data in frail older patients remain limited. The aim of this study was to compare the tolerability of these antibiotics in UTIm patients over age 75 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter retrospective study included patients age \u226575 years who were hospitalized for UTIm in 8 hospitals and treated with oral fluoroquinolone or cotrimoxazole. Adverse events (AEs) during hospitalization were compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 228 patients (median age, 85 years), 131 (57.4%) received fluoroquinolones and 97 (42.6%) cotrimoxazole. Baseline characteristics were similar. AEs occurred in 29.7% of fluoroquinolone-treated patients vs 48.5% treated with cotrimoxazole (P = .006), leading to treatment discontinuation in 2.3% vs 11.3% (P = .009). Acute kidney injury was observed in 7.2% vs 29.4% (P &amp;lt; .001), metabolic disorders in 7.6% vs 18.6% (P = .023). Other AEs and mortality did not differ significantly. Cotrimoxazole was associated with a doubled risk of AEs (adjusted odds ratio, 2.10; 95% CI, 1.18\u20133.74; P = .01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results suggest a better safety profile of fluoroquinolones than cotrimoxazole in the treatment of UTI in older men. These results need to be confirmed in a prospective design.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag271","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T11:48:08Z","timestamp":1778240888000},"source":"Crossref","is-referenced-by-count":0,"title":["Safety of Fluoroquinolones and Cotrimoxazole in Urinary Tract Infections in Older Males"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7432-0113","authenticated-orcid":false,"given":"Camille","family":"Gouraud","sequence":"first","affiliation":[{"name":"Service de Maladies Infectieuses, Centre Hospitalier Intercommunal de Villeneuve Saint Georges , Villeneuve Saint Georges ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4408-554X","authenticated-orcid":false,"given":"Alain","family":"Putot","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne et Maladies Infectieuses, H\u00f4pitaux du Pays du Mont-Blanc , Sallanches ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7201-3850","authenticated-orcid":false,"given":"Thibaut","family":"Fraisse","sequence":"additional","affiliation":[{"name":"Court S\u00e9jour G\u00e9riatrique, Centre Hospitalier Al\u00e8s-C\u00e9vennes , Al\u00e8s ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5753-1465","authenticated-orcid":false,"given":"Messaline","family":"Bermejo","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne et Maladies Infectieuses, Centre Hospitalier de Troyes , Troyes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6160-2713","authenticated-orcid":false,"given":"Benjamin","family":"Viala","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses, Centre Hospitalier Alpes L\u00e9man , Contamine-sur-Arve ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Golstein","sequence":"additional","affiliation":[{"name":"Service de G\u00e9riatrie G\u00e9n\u00e9rale, H\u00f4pital Bretonneau , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nad\u00e8ge","family":"Lemarie","sequence":"additional","affiliation":[{"name":"Service de G\u00e9riatrie Aigue, H\u00f4pital Tenon , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0870-0979","authenticated-orcid":false,"given":"Claire","family":"Roubaud Baudron","sequence":"additional","affiliation":[{"name":"Service de G\u00e9riatrie Aigue, Centre Hospitalier Universitaire de Bordeaux, P\u00f4le de G\u00e9rontologie Clinique, Univ. Bordeaux, BRIC Bordeaux Institute of Oncology INSERM UMR 1312 , Bordeaux ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4832-0161","authenticated-orcid":false,"given":"Pauline","family":"Caraux-Paz","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses, Centre Hospitalier Intercommunal de Villeneuve Saint Georges , Villeneuve Saint Georges ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"2026052815015082000_ofag271-B1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","article-title":"CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting","volume":"36","author":"Horan","year":"2008","journal-title":"Am J Infect Control"},{"key":"2026052815015082000_ofag271-B2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ucl.2015.07.002","article-title":"Bacteruria and urinary tract infections in the elderly","volume":"42","author":"Detweiler","year":"2015","journal-title":"Urol Clin North Am"},{"key":"2026052815015082000_ofag271-B3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/02813432.2020.1794409","article-title":"Different antibiotic regimes in men diagnosed with lower urinary tract infection - a retrospective register-based study","volume":"38","author":"Kornf\u00e4lt Isberg","year":"2020","journal-title":"Scand J Prim Health Care"},{"key":"2026052815015082000_ofag271-B4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.medmal.2018.03.005","article-title":"Practice guidelines for the management of adult community-acquired urinary tract infections","volume":"48","author":"Caron","year":"2018","journal-title":"Med Mal Infect"},{"key":"2026052815015082000_ofag271-B5","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3390\/biomedicines11061633","article-title":"Pharmacokinetics of antibacterial agents in the elderly: the body of evidence","volume":"11","author":"Butranova","year":"2023","journal-title":"Biomedicines"},{"key":"2026052815015082000_ofag271-B6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s40266-023-01019-3","article-title":"Safety and tolerability of antimicrobial agents in the older patient","volume":"40","author":"Soraci","year":"2023","journal-title":"Drugs Aging"},{"key":"2026052815015082000_ofag271-B7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jgar.2020.02.022","article-title":"Considerations for the optimal management of antibiotic therapy in elderly patients","volume":"22","author":"Falcone","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2026052815015082000_ofag271-B8","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"2026052815015082000_ofag271-B9","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jama.2021.9899","article-title":"Effect of 7 vs 14 days of antibiotic therapy on resolution of symptoms among afebrile men with urinary tract infection: a randomized clinical trial","volume":"326","author":"Drekonja","year":"2021","journal-title":"JAMA"},{"key":"2026052815015082000_ofag271-B10","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.idnow.2020.11.003","article-title":"Cotrimoxazole for community-acquired urinary tract infections leads to more adverse effects than fluoroquinolones","volume":"51","author":"Michelangeli","year":"2021","journal-title":"Infect Dis Now"},{"key":"2026052815015082000_ofag271-B11","first-page":"1606","article-title":"Efficacy and safety of ciprofloxacin oral suspension versus trimethoprim-sulfamethoxazole oral suspension for treatment of older women with acute urinary tract infection","volume":"49","author":"Gomolin","year":"2001","journal-title":"J Am Geriatr Soc"},{"key":"2026052815015082000_ofag271-B12","first-page":"446","article-title":"Ofloxacin versus trimethoprim\/sulfamethoxazole in the treatment of uncomplicated urinary tract infection","volume":"14","author":"Cox","year":"1992","journal-title":"Clin Ther"},{"key":"2026052815015082000_ofag271-B13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ijantimicag.2018.04.014","article-title":"Adverse events of fluoroquinolones vs. other antimicrobials prescribed in primary care: a systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Tandan","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2026052815015082000_ofag271-B14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1742-1241.1992.tb10281.x","article-title":"Ofloxacin versus trimethoprim and co-trimoxazole in the treatment of uncomplicated urinary tract infection in general practice","volume":"46","author":"Spencer","year":"1992","journal-title":"Int J Clin Pract"},{"key":"2026052815015082000_ofag271-B15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejim.2020.01.009","article-title":"Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: an umbrella review","volume":"75","author":"Gatti","year":"2020","journal-title":"Eur J Intern Med"},{"key":"2026052815015082000_ofag271-B16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/11531490-000000000-00000","article-title":"Safety considerations of fluoroquinolones in the elderly: an update","volume":"27","author":"Stahlmann","year":"2010","journal-title":"Drugs Aging"},{"key":"2026052815015082000_ofag271-B17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40801-021-00268-1","article-title":"Delirium associations with antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS)","volume":"9","author":"Teng","year":"2022","journal-title":"Drugs - Real World Outcomes"},{"key":"2026052815015082000_ofag271-B18","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1503\/cmaj.111152","article-title":"Considerations when prescribing trimethoprim-sulfamethoxazole","volume":"183","author":"Ho","year":"2011","journal-title":"Can Med Assoc J"},{"key":"2026052815015082000_ofag271-B19","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/jac\/dks030","article-title":"Acute kidney injury associated with trimethoprim\/sulfamethoxazole","volume":"67","author":"Fraser","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2026052815015082000_ofag271-B20","article-title":"Trimethoprim use for urinary tract infection and risk of adverse outcomes in older patients: cohort study","volume":"360","author":"Crellin","year":"2018","journal-title":"BMJ"},{"key":"2026052815015082000_ofag271-B21","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/bcp.70051","article-title":"Safety of sulfamethoxazole-trimethoprim for the treatment of bacterial infection in outpatient settings: a systematic review and meta-analysis with active comparator disproportionality analysis","volume":"91","author":"Preyra","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"2026052815015082000_ofag271-B22","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1186\/s12877-021-02512-3","article-title":"Risk of antimicrobial-associated organ injury among the older adults: a systematic review and meta-analysis","volume":"21","author":"Chinzowu","year":"2021","journal-title":"BMC Geriatr"},{"key":"2026052815015082000_ofag271-B23","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.cmi.2020.02.021","article-title":"Evaluating the risk of hyperkalaemia and acute kidney injury with cotrimoxazole: a retrospective observational study","volume":"26","author":"Rajput","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2026052815015082000_ofag271-B24","author":"FDA Drug Safety Communication"},{"key":"2026052815015082000_ofag271-B25"},{"key":"2026052815015082000_ofag271-B26","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/382690","article-title":"\u201cCollateral damage\u201d from cephalosporin or quinolone antibiotic therapy","volume":"38","author":"Paterson","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2026052815015082000_ofag271-B27","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2217\/fmb.15.40","article-title":"Impact of fluoroquinolones on human microbiota. Focus on the emergence of antibiotic resistance","volume":"10","author":"de Lastours","year":"2015","journal-title":"Future Microbiol"},{"key":"2026052815015082000_ofag271-B28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12915-019-0692-y","article-title":"Distinct impact of antibiotics on the gut microbiome and resistome: a longitudinal multicenter cohort study","volume":"17","author":"Willmann","year":"2019","journal-title":"BMC Biol"},{"key":"2026052815015082000_ofag271-B29","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1093\/cid\/ciad070","article-title":"Antimicrobial for 7 or 14 days for febrile urinary tract infection in men: a multicenter noninferiority double-blind, placebo-controlled, randomized clinical trial","volume":"76","author":"Lafaurie","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026052815015082000_ofag271-B30","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/clinids\/4.2.358","article-title":"Trimethoprim alone in the treatment of urinary tract infections: eight years of experience in Finland","volume":"4","author":"Kasanen","year":"1982","journal-title":"Clin Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag271\/68264305\/ofag271.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/5\/ofag271\/68264305\/ofag271.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/5\/ofag271\/68264305\/ofag271.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T19:01:59Z","timestamp":1779994919000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag271\/8675484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag271","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,28]]},"article-number":"ofag271"}}